PolyPid Ltd. PYPD
At closeNov 6, 2026, 5:46 PM EST
After hours · Nov 6, 5:46 PM ET
- YTD
- +41.47%
- 1 year
- +61.58%
- Market cap
- 124.71M
- EPS (ttm)
- -1.44
- Shares out
- 6.80M
- Forward P/E
- -1.36
- YTD return
- +41.47%
- 1-year return
- +61.58%
- Volume
- 185.61K
- Avg volume
- 118.53K
- Open
- 5.71
- Previous close
- 5.67
- Day's range
- 5.52 – 6.14
- 52-week range
- 3.50 – 6.14
- Beta
- 1.32
- Analysts
- Buy
- Price target
- 11.75 (+91.4%)
- Earnings date
- Feb 12, 2025
2Y +2.72 (+79.53%)
Key statistics
- Enterprise value
- 18.09M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -9.82M
- Total cash
- 9.35M
- Total debt
- 11.03M
- Return on equity
- -496.62%
- Short % of float
- 0.28%
- 50-day average
- 3.28
- 200-day average
- 3.90
Analyst view
Consensus: buy
- Target (low)
- 10.00
- Target (mean)
- 11.75
- Target (high)
- 14.00
- Strong buy2
- Buy1
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 12, 2025
Expected Feb 12, 2025. Consensus EPS estimate -1.03.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 12, 2025 | Dec 1, 2024 | -1.05 | — | — | — |
| Nov 13, 2024 | Sep 1, 2024 | -1.07 | -1.22 | -0.15 | -14.02% |
| Aug 14, 2024 | Jun 1, 2024 | -1.51 | -1.25 | +0.26 | +17.22% |
| Aug 14, 2024 | Jun 1, 2024 | -1.51 | — | — | — |
| May 8, 2024 | Mar 1, 2024 | -1.96 | -1.37 | +0.59 | +30.10% |
| May 8, 2024 | Mar 1, 2024 | -1.96 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 4, 2024 | Craig-Hallum | init | — | Buy |
| Oct 2, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Jun 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 9, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About PolyPid Ltd.
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Israel
- Website
- polypid.com
News
PolyPid: Strong Phase 3 Data Support A Buy Ahead Of November's FDA Decision 
This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday 
This Rubrik Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Thursday 
This Spero Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday 
This PPL Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday 
Oppenheimer Initiates Coverage On PolyPid with Outperform Rating, Announces Price Target of $10 
PolyPid Q2 EPS $(0.35) Beats $(0.38) Estimate 
PolyPid Announces FDA Acceptance Of Its New Drug Application With A Priority Review For D-PLEX100 For The Prevention Of Surgical Site Infections In Patients Undergoing Abdominal Colorectal Surgery; PDUFA Action Date Is November 28 
12 Health Care Stocks Moving In Tuesday's Intraday Session - HC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $13 Price Target
Your note
Sign in to keep a note on PYPD — it syncs with the Stock Master app.
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AIGH Capital Management LLC | 9.99% | 679,668 | 2.50M | Sep 29, 2024 |
| Rosalind Advisors, Inc. | 9.98% | 679,168 | 2.50M | Sep 29, 2024 |
| DAFNA Capital Management, LLC | 4.53% | 308,497 | 1.14M | Sep 29, 2024 |
| Stonepine Capital Management, LLC | 2.04% | 138,504 | 509.69K | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 1.38% | 93,902 | 345.56K | Sep 29, 2024 |
| Yelin Lapidot Holdings Management Ltd. | 0.16% | 11,153 | 41.04K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Fidelity NASDAQ Composite Index Fund | 0.00% | 80 | 294 | Oct 30, 2024 |